

NCT ID	NCT03950154
Title	Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer
Phase	Phase 3
Date Added	2019-05-15
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Bevacizumab Injection [Avastin], capecitabine, oxaliplatin, PD1-T cells
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03947385
Title	Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Phase	Phase 1, Phase 2
Date Added	2019-05-13
Location	California, United States New York, United States North Carolina, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States Australia Canada
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Binimetinib, Crizotinib, IDE196
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03940820
Title	Clinical Research of ROBO1 Specific CAR-NK Cells on Patients With Solid Tumors
Phase	Phase 1/Phase 2
Date Added	2019-05-07
Location	China
Prior IO Allowed	No
CRC-directed	No
Status	Recruiting
Drugs	ROBO1 CAR-NK cells
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03935893
Title	Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
Phase	Phase 2
Date Added	2019-05-02
Location	Pennsylvania, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Fludarabine + Cyclophosphamide combination, Tumor Infiltrating Lymphocytes (TIL)
Tags	MSI-H/ MMRd, MSS/ MMRp

NCT ID	PG545 (pixatimod) in combination with nivolumab
Title	PG545 (pixatimod) in combination with nivolumab
Phase	Phase 1
Date Added	2019-04-26
Location	
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03925662
Title	Mebendazole as Adjuvant Treatment for Colon Cancer
Phase	Phase 3
Date Added	2019-04-24
Location	Egypt
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Folfox with avastin, Mebendazole
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03921684
Title	Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients
Phase	Phase 2
Date Added	2019-04-19
Location	Israel
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	capecitabine, mFOLFOX6, Nivolumab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03911557
Title	Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors
Phase	Phase 2
Date Added	2019-04-11
Location	Kentucky, United States
Prior IO Allowed	No
CRC-directed	No
Status	Active, not recruiting
Drugs	Durvalumab and Tremelimumab
Tags	MSS/ MMRp
NCT ID	NCT03874897
Title	Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.
Phase	Phase 1
Date Added	2019-03-14
Location	China
Prior IO Allowed	No

CRC-directed	No
Status	Recruiting
Drugs	CAR-CLDN18.2 T-Cells, Chemotherapy, PD-1 Monoclonal Antibody
Tags	MSI-H/ MMRd, MSS/ MMRp

NCT ID	NCT03868228
Title	PIPAC for the Treatment of Colorectal Peritoneal Metastases
Phase	Phase 1
Date Added	2019-03-11
Location	United Kingdom
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp